Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumor × sintilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 43 Stomach Neoplasms 35 Carcinoma, Non-Small-Cell Lung 27 Colorectal Neoplasms 17 Esophageal Squamous Cell Carcinoma 13 Nasopharyngeal Carcinoma 10 Lung Neoplasms 10 Rectal Neoplasms 8 Pancreatic Neoplasms 7 Esophageal Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Liver Neoplasms 5 Cholangiocarcinoma 5 Neoplasms 4 Triple Negative Breast Neoplasms 3 Recurrence 3 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Turcot syndrome 2 Thyroid Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Nonsquamous Non-Small Cell Lung Cancer 2 Neuroendocrine Tumors 2 Neoplasm Metastasis 2 Locally Advanced Rectal Cancer 2 Glioblastoma 2

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡